Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma
Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.
Dr. Janku on Longitudinal Monitoring of BRAF V600E Mutation in Urinary Cell-Free DNA
Filip Janku, MD, PhD, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512